Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Finch Therapeutics Group is a biotechnology business based in the US. Finch Therapeutics Group stocks (FNCH.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.77 – an increase of 2.61% over the previous week. Finch Therapeutics Group employs 186 staff and has a trailing 12-month revenue of around $10 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$13.75|
|52-week range||$11.56 - $22.5|
|50-day moving average||$13.9171|
|200-day moving average||$14.5718|
|Wall St. target price||$29.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.675|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-09-10)||2.61%|
|1 month (2021-08-17)||7.59%|
|3 months (2021-06-18)||-14.06%|
|6 months (2021-03-18)||-19.12%|
|Revenue TTM||USD$10 million|
|Gross profit TTM||USD$-25,425,000|
|Return on assets TTM||-18.33%|
|Return on equity TTM||-35.61%|
|Market capitalisation||USD$635.8 million|
TTM: trailing 12 months
There are currently 292,782 Finch Therapeutics Group stocks held short by investors – that's known as Finch Therapeutics Group's "short interest". This figure is 31.1% down from 424,634 last month.
There are a few different ways that this level of interest in shorting Finch Therapeutics Group stocks can be evaluated.
Finch Therapeutics Group's "short interest ratio" (SIR) is the quantity of Finch Therapeutics Group stocks currently shorted divided by the average quantity of Finch Therapeutics Group stocks traded daily (recently around 50133.904109589). Finch Therapeutics Group's SIR currently stands at 5.84. In other words for every 100,000 Finch Therapeutics Group stocks traded daily on the market, roughly 5840 stocks are currently held short.
However Finch Therapeutics Group's short interest can also be evaluated against the total number of Finch Therapeutics Group stocks, or, against the total number of tradable Finch Therapeutics Group stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Finch Therapeutics Group's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Finch Therapeutics Group stocks in existence, roughly 10 stocks are currently held short) or 0.0159% of the tradable stocks (for every 100,000 tradable Finch Therapeutics Group stocks, roughly 16 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Finch Therapeutics Group.
Find out more about how you can short Finch Therapeutics Group stock.
We're not expecting Finch Therapeutics Group to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Everything we know about the Pacer BioThreat Strategy ETF IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
Everything we know about the Planet Labs IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the Samsara IPO, plus information on how to buy in.
Everything we know about the Allbirds IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
Everything we know about the OnlyFans IPO, plus information on how to buy in.
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
Everything we know about the Chobani IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.